(Reuters) - Britain's High Court has found the patent to be invalid on the extended-release version of Seroquel, AstraZeneca's blockbuster antipsychotic, dealing a further blow to a highly profitable franchise.
The ruling followed a patent challenge by units of Teva Pharmaceuticals and Novartis's Sandoz - the two biggest generic drugmakers - as well as Accord Healthcare and Intas Pharmaceuticals, AstraZeneca said on Thursday.
The setback comes as the original instant-release (IR) version of Seroquel faces generic competition in both the United States and Europe later this month.
Thursday, March 22, 2012
UK court invalidates AstraZeneca Seroquel XR patent | Reuters